Sun Pharmaceutical Industries announced that it has secured final approval from US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) to market generic Topamax, topiramate tablets.

Topiramate, is a generic version of epilepsy drug Topamax, owned by Ortho-McNeil Pharmaceutical Inc, a division of Johnson & Johnson.

The tablets are available in four different potencies including 25 mg, 50 mg, 100 mg, and 200 mg.

The twelve-monthly sales of Topamax tabs stood at $2.5 billion in the US.

Topiramate, an anticonvulsant drug, is prescribed for the treatment of epilepsy in both children and adults.

In the majority of cases, the drug can also be used as an antidepressant, most of the time for depressive realism.

In kids, it is also prescribed for treatment of Lennox-Gastaut syndrome, a disorder that causes seizures and developmental delay.

It has been used by psychiatrists to cure bipolar disorder, although it is not FDA approved for this purpose. This drug has been investigated for use in treatment of obesity, especially to aid in the reduction of binge eating, and also as a possible treatment for alcoholism.

The drug is also used in clinical trials to treat Post Traumatic Stress Disorder.

At 01:14 p.m., the company’s stock gained 2.1% at Rs 1,102 on the Bombay Stock Exchange (BSE). The total volume of shares traded was 17,212. The share price has seen a 52-week high of Rs 1,539.90 and a low of Rs 953 on BSE.